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1. Introduction
  Malaria remains a major and growing threat to the public 
health, especially, in the endemic areas[1]. One of the five 
parasite species that infect humans, Plasmodium falciparum 
(P. falciparum) is the most lethal[2]. It is estimated that the 
disease afflicts 450 million and kills 1.5-2.7 million people 
each year[3]. Chemotherapy of malaria is available but is 
complicated by antimalarial drug resistance, including the 
first-line drug artemisinin[4], and their toxicity[5]. Present 
control measures highlight the priority for more effective 
and less toxic new drugs with different mechanism of 
action[6,7]. 
  Pyrimidine nucleotides are essential metabolites. Unlike 
human and other mammalian cells[8], P. falciparum cannot 
salvage preformed pyrimidine bases or nucleosides from 
human host, but relies solely on nucleotides synthesized 
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through the de novo pathway[9]. The pathway involves six 
sequential enzymes catalyzing the conversion of following 
precursors: HCO3
-, ATP, Glu, Asp, and 5-phosphoribosyl-
1-pyrophosphate (PRPP), to form uridine 5’-monophosphate 
(UMP) (Figure 1). There are some key differences in the 
pathway between malaria parasites and higher eukaryotes, 
including human host, for instance, the parasite enzyme 
inhibitors are found to have strong antimalarial activity for 
P. falciparum in vitro and Plasmodium berghei (P. berghei) 
propagated in mice[10-20]. The final two steps of UMP 
synthesis require the addition of ribose 5-phosphate from 
PRPP to orotate by orotate phosphoribosyltransferase (EC 
2.4.2.10, OPRT) to form orotidine 5’-monophosphate (OMP) 
and the subsequent decarboxylation of OMP to form UMP by 
OMP decarboxylase (EC 4.1.1.23, OMPDC). In humans, both 
of these enzymes exist as a bifunctional UMP synthase[8].
Figure 1. Six sequential steps/enzymes in pyrimidine biosynthetic 
pathway. 
The fifth and sixth enzymes in P. falciparum form the heterotetrameric 
(PfOPRT)2(PfOMPDC)2 complex, while the bifunctional UMP synthase 
exert these enzymatic actions in human cell. PRPP stands for 
5-phosphoribosyl-1-pyrophosphate.
  Currently, we have shown that P. falciparum OPRT 
and OMPDC exist physically as a heterotetrameric 
(PfOPRT)2(PfOMPDC)2 enzyme complex containing two 
subunits each of PfOPRT and PfOMPDC, expressed 
and encoded by two separate genes[21,22]. The enzyme 
complex has a catalytic kinetic advantage compared to the 
monofunctional enzyme[23,24]. In addition, both enzymes 
have unique insertions of amino acid sequences[16,22], 
classified as low complexity region (LCR) by having 
single amino acid repeat sequence which was found in all 
Plasmodium species, but not in homologous proteins from 
other organisms[25]. The biochemical function/relevance of 
the LCR is, however, not understood[26]. 
  Here, we further identified protein-protein interfaces 
in the heterotetrameric (PfOPRT)2(PfOMPDC)2 complex of 
the parasite by bifunctional chemical cross-linker, liquid 
chromatography-mass spectrometric analysis and homology 
modeling. We established that the unique insertion LCR 
of the PfOMPDC is responsible for the OPRT-OMPDC 
interaction, which is the first report for the Plasmodium 
species.
2. Materials and methods
2.1. Construction of E. coli expression plasmid
  PfOPRT gene (846 bp) was cloned into pQE30Xa vector 
(Qiagen) using competent Escherichia coli (E. coli)
M15[pREP4] strain. The E. coli cells were grown in LB
medium containing ampicillin and kanamycin[22]. PfOMPDC 
gene (969 bp) was cloned into pTrcHisA vector (Invitrogen) 
using E. coli TOP10 strain and propagated in LB medium
containing only ampicillin[22]. 
2.2. Protein expression and purification of recombinant 
PfOPRT and PfOMPDC
 The E. coli cells harboring the constructed plasmids 
described above were cultivated in their corresponding 
LB media at 37 曟 until the cell density at OD600 nm was 
0.5. They were then induced with 1 mM isopropyl 毬
-D-thiogalactopyranoside for 18 h at 18 曟. The recombinant 
PfOPRT and PfOMPDC proteins were purified by using two 
sequential steps of a nickel-nitrilotriacetic acid (Ni-NTA) 
metal-affinity chromatography (Qiagen) and a superose 
12 gel filtration fast protein liquid chromatography (FPLC) 
(Amersham Biosciences) as previously described[16,22].  
2.3. Protein and enzymatic assay
  Protein concentrations were determined by the Bradford 
assay[27] with bovine serum albumin as standard. PfOPRT 
and PfOMPDC activities were measured at 37 曟 in quartz 
cuvette using a UV-visible Shimadzu spectrophotometer 
model UV 1601 with a temperature control device[21]. 
2.4. Chemical cross-linking of PfOPRT and PfOMPDC
  In vitro formation of heterotetrameric (PfOPRT)2(PfOMPDC)2 
complex or dimeric forms of either (PfOPRT)2 or (PfOMPDC)2 
were carried out by bifunctional chemical cross-linking 
using 3,3’-dimethyl suberimidate (DMS) which linked 
peptides having the nearest neighbors of Lys residues at 
-NH2 groups to yield amidine derivative of the peptides with 
a maximum link distance of 1.0 nm[22]. 
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2.5. SDS-Polyacrylamide gel electrophoresis
 SDS-PAGE was performed on a Bio-Rad minislab gel 
apparatus with 5% stacking and varying acrylamide 
percentages of running gels[28]. Gels were stained with 
Coomassie Brilliant Blue R-250 dye.
2.6. In-gel digestion
  Visualized protein bands in the SDS-PAGE gel were cut 
into small pieces and destained extensively with 50 mM
NH4HCO3 followed by methanol prior to washing with 
deionized water. Chopped gels were dehydrated in 
acetonitrile and reduced with 10 mM dithiothreitol in 10 mM 
NH4HCO3 for 1 h at 56 曟. Reduced gels were then alkylated 
by 100 mM iodoacetamide in 10 mM NH4HCO3 for 1 h at 25 曟 
in dark. Alkylated gels were further digested with 10 ng/毺L
sequencing grade trypsin in 10 mM NH4HCO3 for 3 h at 
37 曟. Trypsin digested peptides were eluted from the gels 
with 0.1% formic acid/50% acetonitrile, evaporated at 40 曟 
overnight, and then stored at -20 曟 until use[29]. 
2.7. Liquid chromatography-mass spectrometry and 
proteomic data analysis 
  Nanoscale LC separation of tryptic peptides was performed 
with a NanoAcquity system (Waters Corp.) equipped with 
a symmetry C18 5 毺m, 180 毺m 暳 20 mm Trap column 
and a BEH130 C18 1.7 毺m, 100 毺m 暳 100 mm analytical 
reversed-phase column (Waters Corp.). The samples were 
initially transferred with 0.1% formic acid to the trap column 
with a flow rate of 15 毺L/min for 1 min. Mobile phase A 
was 0.1% formic acid in water, and mobile phase B was 0.1% 
formic acid in acetonitrile.  The peptides were separated 
with a gradient of 15%-50% mobile phase B over 15 min at a 
flow rate of 500 nL/min followed by a 3 min rinse with 80% 
of mobile phase B. The column temperature was maintained 
at 35 曟.  The lock mass was delivered from the auxiliary 
pump of the NanoAcquity pump with a constant flow rate of
500 nL/min at a concentration of 200 fmol/毺L of 
[Glu1]fibrinopeptide B to the reference sprayer of the 
NanoLockSpray source of the mass spectrometer.  
  Analysis of tryptic peptides was performed using a 
SYNAPT
TM HDMS mass spectrometer (Waters Corp.). For 
all measurements, the mass spectrometer was operated in 
the V-mode of analysis with a resolution of at least 10 000 
full-width half-maximum. All analyses were performed 
using positive nanoelectrospray ion mode. The time-of-
flight (TOF) analyzer of the mass spectrometer was externally 
calibrated with [Glu1]fibrinopeptide B from m/z 50 to 1 600 
with acquisition lock mass corrected using the monoisotopic 
mass of the doubly charged precursor of [Glu1]fibrinopeptide 
B. The reference sprayer was sampled with a frequency of 20 s.
Accurate mass LC-MS data were acquired with data direct 
acquisition mode. The trap collision energy was 6 V, transfer 
collision energy was 4 V. The quadrupole mass analyzer was 
adjusted such that ions from m/z 300 to 1 800 were efficiently 
transmitted.  The MS/MS was recorded in the range of 50 
to 1 990 Da with a scan time of 0.5 s/scan. The MassLynx 
version 2.3 software was applied to analyze the LC-MS/MS 
data.  
2.8. Homology modeling of PfOPRT and PfOMPDC in 
monomer, dimer and heterotetramer
  The three-dimensional (3D) structures of PfOPRT 
(residues 64-281) and PfOMPDC (residues 1-323) were, 
respectively, determined by using crystal structures of 
Saccharomyces cerevisiae (S. cerevisiae) OPRT (PDB code 
2PS1, chain A) and P. falciparum 3D7 OMPDC (PDB 
code 2Q8Z, chain A) as template. Homology models of 
the structures were generated by the Phyre program[30]. 
Homology search and multiple alignment of amino acid 
sequences were performed using the BLAST[31] and the 
CLUSTALW[32] programs, respectively. After the binding 
sequences identified by LC-MS/MS data, models for 
protein-protein interactions of dimeric  (PfOPRT)2 and 
(PfOMPDC)2, and heterotetrameric (PfOPRT)2(PfOMPDC)2 
were generated. The constructed dimeric models were 
stereo rotated with the amino acid sequences used for 
binding between chain A and chain B of PfOPRT and 
PfOMPDC. The dimeric models were then applied as the 
template to generate heterotetrameric model by further 
stereo rotating with the amino acid sequences identified 
for PfOPRT-PfOMPDC interactions. 
3. Results
3.1. Chemical cross-linking of PfOPRT and PfOMPDC
  The recombinant PfOPRT and PfOMPDC proteins 
expressed in E. coli were purified by two sequential steps 
of a Ni-NTA-affinity chromatography and a superose 12 gel 
filtration column on FPLC system. The recombinant PfOPRT 
and PfOMPDC were catalytically active in its dimeric form 
and had specific activities of 4.7 and 7.9 毺mol/min per 
mg protein, respectively. Using this strategy, we obtained 
3-4 mg each of nearly 95% pure and active PfOPRT and 
PfOMPDC from 1 L of cell culture. By gel filtration FPLC and 
SDS-PAGE, the PfOPRT was a 67 kDa homodimer of two
33 kDa (PfOPRT)2 subunits (Figure 2A), whereas the 
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PfOMPDC showed a monomeric subunit of 38 kDa (Figure 2B) 
and a 76 kDa homodimeric (PfOMPDC)2. To prepare chemical 
cross-linked products of PfOPRT and/or PfOMPDC, the 
pure enzyme was incubated at 25 曟 with DMS at a ratio of 
1:2 protein to cross-linker[22]. By SDS-PAGE, monomers 
and dimers of (PfOPRT)2 and (PfOMPDC)2 were detected. 
Chemical cross-linked heterotetrameric form of PfOPRT and 
PfOMPDC was achieved by further DMS treatment at a ratio 
of 1:2 protein to cross-linker. After 30 min incubation, more 
than 50% of the proteins were cross-linked as tetrameric 
form (Figure 2C). The time-dependent oligomerization of 
each enzyme corresponded to that expected for sequential 
cross-linking of monomer to form dimer, and each dimer to 
form heterotetramer. The molecular mass of each oligomer 
was determined as previously described[22].  
Table 1
LC-MS/MS data analysis of P. falciparum orotate phosphoribosyltransferase in monomeric, dimeric forms and in heterotetrameric complex with 
orotidine 5’-monophosphate decarboxylase. 
Peptide Peptide score a MH+ (Da) Monomeric OPRT Dimeric OPRT Tetrameric OPRT-OMPDC
ENEFLCDEEIYK   34.340 000 1 032.689 1   5.811 603 10.671 790 7.537 772
EYGDKNVIVGNLDDDDKDILNLKK   15.600 000 2 713.714 6   8.755 316 - 5.822 202
GIPMVSLTSHFLFESK   85.930 000 1 504.672 6   7.166 355   6.090 981 6.881 962
IYFKDIFEK   44.310 001 1 194.595 1   7.241 354   5.591 504 6.965 446
KNIIIIDDVFTCGTALTEILAK   71.029 999 2 461.818 3   7.857 266   4.154 335 -
KYSNIFYLYDR   68.019 997 1 089.601 6 10.809 390   7.890 219 7.214 506
LSFDYLLGASYK   60.650 002 1 375.949 4   7.222 945   3.474 503 7.305 166
NVIVGNLDDDDK   50.020 000 1 154.303 4   5.289 937   5.497 626 6.619 940
NVIVGNLDDDDKDILNLK 103.830 000 2 013.217 9 14.657 430   4.562 683 5.403 011
NVIVGNLDDDDKDILNLKK   35.790 001 2 122.657 7   9.319 596 - 6.336 068
SFVHLK     8.360 000    499.332 6   7.925 779   6.753 919 8.925 819
VGIPLYSILSYK   61.270 000 1 183.736 7   4.989 854   6.546 392 6.391 722
VVAFIVLLNR   47.689 999 1 144.144 1   6.420 709   9.936 290 6.922 265
VVAFIVLLNRNEYEINENNQK   33.000 000 2 520.391 1   9.863 172   4.334 970 4.282 399
YSNIFYLYDR   73.480 003 1 353.232 0 13.433 300 10.828 940 9.282 876
YSNIFYLYDRK   26.860 001 1 481.522 2   4.393 924   9.054 119 6.417 926
a
The results were tested by the Decyder MS program with significance at P<0.05.
Table 2
LC-MS/MS data analysis of P. falciparum orotidine 5’-monophosphate decarboxylase in monomeric, dimeric forms and in heterotetrameric 
complex with orotate phosphoribosyltransferase.
Peptide Peptibe score MH+ (Da) Monomeric OMPDC Dimeric OMPDC Tetrameric OPRT-OMPDC
AAQMYYDQINAILK 58.610 001 2 210.549 1 13.511 260  13.359 900 12.414 570
APDNIIR 45.570 000 1 000.651 4   8.347 193   7.843 130   7.181 398
APDNIIREEK 41.049 999 1 180.240 4   9.541 573   5.696 492   4.269 348
DICYDEEK 18.820 000 1 065.693 5 10.504 400   4.767 869   9.609 203
DICYDEEKNK 21.639 999 1 313.594 6   6.805 417 -   3.950 628
DILLKAPDNIIR 40.070 000 1 374.595 9   5.955 823    7.277 666   6.832 736
DILLKAPDNIIREEK   9.010 000 1 766.359 0   7.218 944    8.964 727   5.962 379
FIFEYLK 22.330 000 4 811.505 1 10.328 490    7.360 944 -
ILINIGR 26.360 001    800.088 8   7.875 441    5.720 076   5.588 307
INDIGNTVK 36.799 999    976.666 6   8.848 516    6.200 231   3.874 776
KFIFEYLK 25.840 000 1 089.976 7   9.965 045    5.086 093   6.271 910
MNFAFYIPYGSVGIDVLK 46.419 998 1 422.111 6   6.851 215    5.939 178   4.606 118
NAINTCLCIGLDPDEK 80.889 999 1 833.055 4   6.117 382    9.577 628 -
NAINTCLCIGLDPDEKDIENFMK 24.330 000 2 139.558 1   6.240 061    5.302 535   5.325 563
NVFDYLYELNIPTILDMK 62.799 999 2 217.121 0 14.356 230  10.730 460 -
SDSCTVNIYMGTNMLK 41.169 998 1 388.550 8   5.956 773    4.115 105   4.277 855
SEEFFYFFNHFCFYIINETNK 29.080 000 2 047.242 8   6.717 936    5.769 700 -
TTNPDSAIFQK 59.430 000 1 221.389 4 14.289 200  13.020 870   6.978 079
TTNPDSAIFQKNLSLDNK 25.290 001 1 985.607 7   8.036 843    7.232 890   6.672 452
TYFPNCYILSPGIGAQNGDLHK 41.490 002 2 463.589 0   8.362 220  11.827 000   5.371 594
YALTFK 20.879 999 3 332.587 9 12.878 050    5.566 563   8.408 722
YINNVSIK 23.230 000 4 797.700 2   8.022 080    6.701 042 -
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Figure 2. SDS-PAGE analysis of monomeric, dimeric and tetrameric 
forms in P. falciparum OPRT and OMPDC. 
The oligomers of  PfOPRT and/or PfOMPDC, which were cross-linked 
by reacting with 3,3’-dimethyl suberimidate,  were identified on 7%-
12% polyacrylamide gels. (A) PfOPRT cross-linked dimeric form on 
12% gel, lane 1: molecular mass standard, lane 2: the non-cross-
linking monomeric form (10 毺g protein), lanes 3, 4: cross-linking 
products of dimeric form after 15 and 30 min reactions. Monomer on 
lane 2 and dimeric product on lane 4 gels were excised for LC-MS/MS 
analysis. (B) PfOMPDC chemically cross-linked dimeric form on 7% 
gel, lane 1: molecular mass standard, lane 2: the non-cross-linking 
monomeric form (20 毺g protein), lane 3: cross-linking products 
of the dimeric form after 30 min reaction. Monomer on lane 2 and 
dimeric product on lane 3 gels were excised for LC-MS/MS analysis. 
(C) PfOPRT and PfOMPDC cross-linked tetrameric form on 10% gel, 
lane 1: molecular mass standard, lane 2: the non-cross-linking 
monomeric form (10 毺g protein each), lanes 3-6: cross-linking 
products of tetrameric form after 10, 20, 30 and 60 min reactions. 
Tetrameric product on lane 4 gel was excised for LC-MS/MS analysis. 
The apparent monomer, dimer, and tetramer have log molecular mass 
of 4.58, 4.85, and 5.15, respectively.
3.2. Liquid chromatography-mass spectrometry of chemical 
cross-linking products
  The non cross-linked monomeric forms, cross-linked 
dimeric and heterotetrameric forms on the SDS-PAGE 
gel were subjected to in-gel trypsin digestion. The entire 
peptide samples were injected into the HPLC Q-TOF, and 
the LC-MS/MS data were analyzed by the MassLynx software 
and summarized in Table 1 for PfOPRT and Table 2 for 
PfOMPDC. The results showed the amino acid sequences 
of PfOPRT and PfOMPDC obtained as monomer, dimer, 
and heterotetramer forms. Combining the chemical cross-
linking and LC-MS/MS led us to identify amino acid 
sequences that play role in the binding between domains 
and/or polypeptide chain of individual and both enzymes. 
The blank spaces in the Tables 1 and 2 represent the cross-
linked peptides/sequences. Amino acid sequences that were 
present in the monomeric form but was not in the dimeric or 
heterotetarmeric form confirms that this sequence underlies 
domain-domain interface and contains amino acid residues 
used for binding between domains. 
3.3. Homology models and proteomic data analysis
  As for the homology model, the Phyre program was utilized 
to construct models of PfOPRT and PfOMPDC. The model of 
PfOPRT had no N-terminal domain (residues 1-63) which 
has the unique insertion LCR sequence (Figure 3). This 
N-terminal sequence contained one 毩-helix (residues 13-
36). Sequence alignment between PfOPRT and S. cerevisiae 
OPRT showed 30% identity. The most striking finding in all 
Plasmodium OPRTs were two large insertions; one, at the 
N-terminal region as described above and, another, at the 
internal region (residues 178-196) with a high hydrophobic 
index of +1 to +3[16]. 
Figure 3.  Sequence alignment of OPRTs. 
Sequence alignment of seven different OPRTs was performed using 
CLUSTALW[32]. Species name and accession numbers are as follows: 
P. falciparum OPRT (PFE0630C), Plasmodium knowlesi(P. knowlesi) 
(XP_002259686.1), Plasmodium vivax (P. vivax) (XP_001613829),
P. berghei (PBANKA_111240), S. cerevisiae (NP_013601), E. coli (X00781) 
and Homo sapiens (H. sapiens) (NP_000364). Conserved identical 
residues are highlighted in yellow, similar residues are shown in pink. 
In P. falciparum sequence, LCRs are bold and italic letters, cross-
linking peptides are shown with yellow drag, sequences 168-191 
and 202-223 are responsible for homodimeric and heterotetrameric 
formation, respectively. The Phyre program was used to predict
毩-helix and 毬-strand in the N-terminal sequence (residues 1-63), 
having one 毩-helix (residues 13-36) and no 毬-strand[30]. 
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  Based on the sequence alignments of OMPDCs from 
available Plasmodium species, the model for PfOMPDC 
using the full-length sequence contained a large unique 
insertion LCR in the 毩2, 毩3, 毩4 and 毩5 helices at the 
N-terminal domain which were found in all Plasmodium 
OMPDCs (Figure 4)[22]. 
Figure 4. Sequence alignment of OMPDCs. 
Sequence alignment of seven different OMPDCs was performed using 
CLUSTALW[32]. Species name, accession numbers and PDB ID are as 
follows: P. falciparum OMPDC (2ZA2), P. knowlesi (XP_002261749.1), 
P. vivax (2FFC), P. berghei (2FDS), S. cerevisiae (1DQW), E. coli (1L2U) 
and H. sapiens (2EAW). Conserved identical residues are highlighted in 
yellow, similar residues are shown in pink. In P. falciparum sequence, 
LCRs are bold and italic letters, cross-linking peptides are shown with 
yellow drag, sequence 175-184 is used for homodimeric formation, 
sequences 12-27, 52-59, 76-96, 121-138 and 152-158 are responsible 
for heterotetrameric formation.
  The monomeric PfOPRT model consisted of 6 毩-helices 
and 11 毬-strands (Figure 5A), while the monomeric 
PfOMPDC structure model exhibited 13 毩-helices and 8 毬
-strands (Figure 5B). Both enzymatic models highlight the 
LCR sequences that conserve amongst Plasmodium species, 
and participate in homodimeric and heterotetrameric 
formation.
Figure 5. Phyre homology model of monomeric P. falciparum OPRT 
and OMPDC.
The Phyre program was used to predict 毩-helix and 毬-strand[30]. 
The 毩-helix numberings are shown in the built models, while the
毬-strands are not shown here but details can be found in the 
sequence alignments for PfOPRT (Figure 3) and PfOMPDC (Figure 
4). (A)  PfOPRT model (64-281 residues) is depicted with the 1-63 
residues omitted from the Phyre program due to its unique insertion 
sequence LCR with very low identity to other OPRTs. The model shows 
LCRs, 毩4 and 毩8 that used for dimeric and tetrameric formation 
(green ribbon 毩-helix and 毬-strand). The active site was identified 
using Swiss model as previously described[45]. (B) PfOMPDC model 
(1-323 residues) is a completed full-length sequence in which its 
N-terminus harboring 毩2, 毩3, 毩4, and 毩5-helices as unique 
insertions (LCRs) to the enzyme, and they play role in dimeric and 
tetrameric formation (green ribbon 毩-helices). The active site was 
identified based on our previously described crystal structure[35].
  The LC-MS/MS data of PfOPRT (Table 1) identified the 
sequence 168-EYGDKNVIVGNLDDDDKDILNLKK-191 and 
173-NVIVGNLDDDDKDILNLKK-191 containing amino 
acids responsible for 毬7 strand (residues 165-169), in 毬 
turn at 毬7-毬8 position (residues 170-176) and 毬8 strand 
(residues 177-199), which presumably locate at domain-
domain interface and bind between chain A and chain B of 
PfOPRT (Figure 6A). Interestingly, this binding sequence is 
a main part of the internal unique insertion LCR (residues 
178-196) of PfOPRT (highlighted in Figure 3)[16]. In contrast, 
the LC-MS/MS data of PfOMPDC (Table 2) showed the 
sequence 175-DICYDEEKNK-184, which was not a LCR 
insertion sequence and  located in 毬8 helix (residues 173-
176) (highlighted in Figure 4)[22], as the one for binding 
between chain A and chain B of PfOMPDC (Figure 6B).        
 Furthermore, the LC-MS/MS data of heterotetrameric 
(PfOPRT)2 (PfOMPDC)2 complex (Tables 1 and 2) indicated 
that the sequence 202-KNIIIIDDVFTCGTALTEILAK-
223, spanning in 毩4 helix (residues 214-225) of PfOPRT 
(Figure 6A and 6C),  was used to bind between the 
dimeric (PfOPRT)2 and the dimeric (PfOMPDC)2 at five 
positions as follows: 12-NAINTCLCIGLDPDEK-27 in毩
2 helix; 52-YINNVSIK-59 in毬turn at毩3-毩4 position; 
76-SEEFFYFFNHFCFYIINETNK-96 in毩5 helix; 121-
NVFDYLYELNIPTILDMK-138 in毩6 helix; and 152-
FIFEYLK-158, partially covering in毩7 helix (Figure 6B 
and 6C) of PfOMPDC. All peptides involve in the tetrameric 
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formation as described above are highlighted with yellow 
color on P. falciparum amino acid sequences (Figures 3 
and 4). In addition, the peptide 12-NAINTCLCIGLDPDEK-
27 (Table 2) was cross-linked using K27 to the peptide 202-
KNIIIIDDVFTCGTALTEILAK-223 of PfOPRT (Table 1) to form 
heterotetrameric (PfOPRT)2(PfOMPDC)2, whereas the peptide 
12-NAINTCLCIGLDPDEKDIENFMK-34 of PfOMPDC (Table 
2) was not cross-linked with DMS and it was then digested 
with trypsin when the enzyme stayed in its dimeric form. 
These results suggest that the conformational change occurs 
during heterotetrameric association of dimeric (PfOPRT)2 
and (PfOMPDC)2 (Figure 6 C).                 
Figure 6. Proposed homology model of P. falciparum OPRT and 
OMPDC in dimeric and heterotetrameric forms. 
The models were constructed by the Phyre program[30]. (A) Model 
of dimeric (PfOPRT)2. (B) Model of dimeric (PfOMPDC)2. (C) Model of 
heterotetrameric (PfOPRT)2(PfOMPDC)2 complex. In A and B, light 
green ribbons represent the cross-linking and interacting sites for 
dimeric (PfOPRT)2 and dimeric (PfOMPDC)2, respectively. In C, yellow 
ribbons indicate locations of protein-protein interface and cross-
linking sequences for the heterotetrameric (PfOPRT)2(PfOMPDC)2 
formation.
                                                             
   It is noted here that, the sequence 202-223 (毩4 helix) of 
PfOPRT and 76-96 (毩5 helix) of PfOMPDC were only located 
in the domain-domain interface of the heterotetrameric 
(PfOPRT)2(PfOMPDC)2. Indeed, the 毩2 and 毩5 helices, 
responsible for domain-domain interactions, are unique 
insertion LCR sequences located at the N-terminal 
extension of PfOMPDC[22]. 
  Based on the identified binding sequences by LC-MS/MS 
data, the structural models for protein-protein interactions 
of  dimeric (PfOPRT)2 and (PfOMPDC)2, and heterotetrameric 
(PfOPRT)2(PfOMPDC)2 are then proposed and shown in Figure 6. 
4. Discussion
  Recent findings have highlighted the potential 
vulnerability of the human parasite toward agents which 
affect the pyrimidine biosynthetic pathway[12-20]. However, 
at present only three enzymes have crystal structures and 
crystallographic analyses: the fourth[17], fifth (PfOPRT)[33], 
and sixth (PfOMPDC)[34,35] enzymes of the P. falciparum 
pathway. Much importance has been given to these enzymes 
since compounds presumed to affect the enzyme activities 
have been shown to be selectively toxic toward the human 
parasite[17,18,20]. In humans and most eukaryotes, the 
genes encoding OPRT and OMPDC are fused into OPRT-
OMPDC and expressed as bifunctional UMP synthase[36,37], 
although an inversely linked OMPDC-OPRT gene, where the 
OMPDC is located at N-terminus and OPRT at C-terminus, 
have been reported in the trypanosomatid Leishmania 
donovani[38]. With one exception, both genes in the human 
malarial parasites are acquired from eubacterial origins, 
are located on different chromosomes, and expressed as 
a heterotetrameric (PfOPRT)2(PfOMPDC)2 complex with in 
vivo concentration of 30-46 nM, relatively close to the UMP 
synthase concentration (17-32 nM) in human cells[16,21,22]. 
The structural complex of the parasite enzyme, thus, 
represents an efficient functional kinetic advantage, which is 
in line with co-localization principles for evolutional origin, 
and allosteric control in protein-protein interactions[39,40].
  We have, for the first time, examined the protein-protein 
interactions of the heterotetrameric (PfOPRT)2(PfOMPDC)2 
complex  using chemical cross-linking between the nearest 
Lys residues, and mapping the sites of the cross-link with 
the LC-MS/MS analysis, as previously described for protein 
structural model[41-43]. Aside from establishing the domain-
domain interactions between the PfOPRT (毩4 helix) and 
PfOMPDC (毩2, 毩5, 毩6, 毩7 helices, and 毬 turn at 毩
3-毩4 position) complex, we have also shown that each 
PfOPRT (毬7 and 毬8 strands) and PfOMPDC (毩8 helix) 
form a relatively tight dimeric structure. Our Phyre structural 
model of PfOPRT is comparable to the recent report of 
the Swiss model using the same template of S. cerevisiae 
OPRT[44], in which the unique insertion of 63 amino acids 
from N-terminus is omitted due to its low identity[45]. 
Chemical cross-linking and LC-MS/MS results indicate 
that: 1) the dimer (PfOPRT)2 uses LCR insertion sequences 
for interaction between chain A and B, 2) the dimer 
(PfOMPDC)2 is homologous to all known monofunctional 
OMPDC structures[35,38,46], and 3) the tetramer assembling 
each dimer of (PfOPRT)2 and (PfOMPDC)2 utilizes both the 
LCR sequences (毩2 and 毩5 helices of PfOMPDC) and 
the over-represented hydrophobic amino acid sequences 
with some acidic and basic residues (毩6 and 毩7 helices, 
毬 turn at 毩3-毩4 position of PfOMPDC; 毩4 helix of 
PfOPRT) for the interactions. The 毩2 and 毩5 helices are 
located at a protruding domain in the crystal structure 
of PfOMPDC[35]. In contrast, the bifunctional Leishmania 
donovani and human UMP synthase structural models do not 
possess any significant domain-domain contacts between 
OPRT and OMPDC[38]. Hence, the formation of tetrameric 
(PfOPRT)2(PfOMPDC)2 is unique in the case of the insert LCR 
sequence in the PfOMPDC that found in all Plasmodium 
species plays a functional role for domain-domain 
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interactions. The present investigation clearly supports our 
recent hypothesis that the unique insertions are responsible 
for PfOPRT-PfOMPDC assembly formation in vivo[22,35].
  The origin of LCR in the malarial parasite proteins remains 
unknown. The insertion LCR sequences and binding 
sequences identified in both PfOPRT and PfOMPDC contain 
acid, basic and hydrophobic amino acids, particular 
aromatic residues. Taken together, it is plausible that the 
interactions between PfOPRT and PfOMPDC domains 
apparently favored in the interfaces include mainly the 
hydrophobic pairs and some opposite charged pairs or salt 
bridges, which are supported by computational prediction 
of protein-protein interfaces[47-50]. This conclusion appears 
to agree well with previous results on hyperthermostability 
of the (PfOPRT)2(PfOMPDC)2 complex, comparing to the 
monofunctional form[23].
  Since the actual protein interfaces are inferred from 
X-ray crystallographic structures[51,52], further studies on 
the crystal structural analyses of the enzyme complex with 
full length proteins will provide additional information on 
the binding mechanisms including solvent-inaccessible 
area, hydrogen bonds, salt bridges, interface residues, and 
solvation free-energy between the two domains. Use of 
the interface peptides or inhibitors to disrupt the complex 
formation can be exploited for a rational drug design 
approach for more potential antimalarials[53,54].
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